OTC · MICR
Micron Solutions, Inc.
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
Loading market information…
OTC · MTEM · USD
Stock price, earnings
Quote as of Aug 13, 2025, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Molecular Templates, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Molecular Templates, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments. Currently, several of its ETB candidates are undergoing Phase I clinical evaluation: MT-5111 is being assessed for HER2-positive cancers; MT-0169 is in trials for individuals with relapsed or refractory myeloma; and MT-6402 targets patients who have not responded to prior PD-1/PD-L1 antibody treatments. Beyond these, Molecular Templates is also developing ETBs to engage other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. Furthermore, the company has forged a collaborative partnership with Bristol Myers Squibb to jointly discover and advance innovative ETB-based products designed for a diverse array of biological targets. Established in 2001, Molecular Templates, Inc. is headquartered in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $36.63M+1,469.81% vs estimate |
| Q4 2022 | Mar 27, 2023 | -$0.18+40.0% vs estimate | $2.61M-70.36% vs estimate |
|---|
| Q3 2022 | Nov 10, 2022 | -$6.60-1,275.0% vs estimate | $4.24M+37.66% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (+900.0%)
Beleave Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00-$0.00 (-99.0%)
EPIRUS Biopharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00-$0.00 (-100.0%)
MDEChem, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Discover Wellness Solutions Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Orchid Ventures, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00+$0.00 (0.0%)
Arch Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
